Marker Therapeutics (MRKR) Price & Analysis

Compare

573 Followers

MRKR Stock Chart & Stats

$1.03

-$0.17(-5.70%)

At close: Jan 08 4:00 PM EST

$1.03

-$0.17(-5.70%)

Day’s Range― - ―

52-Week Range$0.81 - $5.95

Previous CloseN/A

Volume39.59K

Average Volume (3M)230.84K

Market Cap

$11.19M

Enterprise ValueN/A

Total Cash (Recent Filing)$10.46M

Total Debt (Recent Filing)$0.00

Price to Earnings (P/E)―

Beta1.76

Next Earnings

Mar 12, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)N/A

Shares Outstanding12,938,910

10 Day Avg. Volume121,789

30 Day Avg. Volume230,837

Financial Highlights & Ratios

PEG Ratio0.07

Price to Book (P/B)1.50

Price to Sales (P/S)4.24

P/FCF Ratio-2.56

Enterprise Value/Market Cap0.00

Enterprise Value/Revenue0.00

Enterprise Value/Gross Profit0.00

Enterprise Value/Ebitda0.00

Forecast

1Y Price Target

$8.00

Price Target Upside676.70% Upside

Rating ConsensusModerate Buy

Number of Analyst Covering1

EPS Forecast (FY)-1.5

Revenue Forecast (FY)$2.65M

Bulls Say, Bears Say

Bulls Say

Clinical TrialsMarker's MT-601 shows a promising 78% overall response rate and 44.4% complete response in B-Cell lymphoma patients who failed or were ineligible for CD19 CAR-T therapy.

Market OpportunityMarker estimates a market opportunity of approximately $1.7 billion for relapsed lymphoma patients after CAR-T therapy, highlighting the potential for significant revenue growth.

Regulatory ProgressAnalyst anticipates updated MT-601 Phase 1 APOLLO data, including more patients, followed by a pivotal trial discussion with FDA, indicating potential regulatory advancements.

Bears Say

Marker Therapeutics News

Marker Therapeutics appoints Penkus Corzo to board of directors

Marker Therapeutics (MRKR) announced the appointment of Kathryn Penkus Corzo, R.Ph., MBA to the Company’s Board of Directors,...

6d ago

MRKR

Marker Therapeutics Strengthens Board with New Appointment

Marker Therapeutics ( ($MRKR) ) has shared an announcement. Marker Therapeutics has appointed Kathryn Penkus Corzo to its...

6d ago

MRKR

Marker Therapeutics’ Innovative Approach in AML and MDS Treatment: A Study Update

Marker Therapeutics (($MRKR)) announced an update on their ongoing clinical study. Study Overview: Marker Therapeutics is conducting a...

15d ago

MRKR

Marker Therapeutics’ MT-601 Study: A Promising Step in Lymphoma Treatment

Marker Therapeutics (($MRKR)) announced an update on their ongoing clinical study. Marker Therapeutics is conducting a Phase 1...

15d ago

MRKR

Marker Therapeutics Advances Off-the-Shelf T Cell Therapy with First Patient Treatment

An announcement from Marker Therapeutics ( ($MRKR) ) is now available. Marker Therapeutics has announced the treatment of...

1M ago

MRKR

Marker Therapeutics announces first patient treated in off-the-shelf program

Marker Therapeutics (MRKR) announced that the first patient has been treated in the Company’s OTS program, with encouraging...

1M ago

MRKR

Marker Therapeutics Reports Promising Phase 1 Study Results

Marker Therapeutics ( ($MRKR) ) just unveiled an announcement. On August 26, 2025, Marker Therapeutics announced encouraging results...

3M ago

MRKR

Marker Therapeutics provides update on observations from Phase 1 APOLLO study

Marker Therapeutics (MRKR) provided an update on the progress and clinical observations from the Phase 1 APOLLO study....

3M ago

MRKR

Marker Therapeutics Reports Increased R&D Expenses Amid Revenue Decline

Marker Therapeutics ( ($MRKR) ) has released its Q2 earnings. Here is a breakdown of the information Marker...

3M ago

MRKR

Promising Developments and Market Potential Drive Buy Rating for Marker Therapeutics

In a report released yesterday, John Newman from Canaccord Genuity maintained a Buy rating on Marker Therapeutics, with...

3M ago

MRKR

Strategic Collaborations and Promising Clinical Developments Drive Buy Rating for Marker Therapeutics

In a report released yesterday, John Newman from Canaccord Genuity maintained a Buy rating on Marker Therapeutics (MRKR...

5M ago

MRKR

Marker Therapeutics Partners with Cellipont for MT-601 Manufacturing

Marker Therapeutics ( ($MRKR) ) just unveiled an update. On June 16, 2025, Marker Therapeutics entered into a...

5M ago

MRKR

Marker, Cellpoint announce collaboration for cGMP manufacturing of MT-601

Marker Therapeutics (MRKR) announced a collaboration with Cellipont Bioservices, a leading cell therapy Contract Development and Manufacturing Organization,...

5M ago

MRKR

Marker Therapeutics Concludes Annual Stockholders Meeting

Marker Therapeutics ( ($MRKR) ) just unveiled an update. On June 6, 2025, Marker Therapeutics held its Annual...

5M ago

MRKR

MRKR FAQ

What was Marker Therapeutics’s price range in the past 12 months?

Marker Therapeutics lowest stock price was $0.81 and its highest was $5.95 in the past 12 months.

What is Marker Therapeutics’s market cap?

Marker Therapeutics’s market cap is $11.19M.

When is Marker Therapeutics’s upcoming earnings report date?

Marker Therapeutics’s upcoming earnings report date is Mar 12, 2026 which is in 121 days.

How were Marker Therapeutics’s earnings last quarter?

Currently, no data Available

Is Marker Therapeutics overvalued?

According to Wall Street analysts Marker Therapeutics’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Marker Therapeutics pay dividends?

Marker Therapeutics does not currently pay dividends.

What is Marker Therapeutics’s EPS estimate?

Marker Therapeutics’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Marker Therapeutics have?

Marker Therapeutics has 12,938,910 shares outstanding.

What happened to Marker Therapeutics’s price movement after its last earnings report?

Currently, no data Available

Which hedge fund is a major shareholder of Marker Therapeutics?

Currently, no hedge funds are holding shares in MRKR

Company Description

Marker Therapeutics

Marker Therapeutics, Inc. (MRKR) is a clinical-stage immuno-oncology company specializing in the development of innovative cell therapies for the treatment of hematological malignancies and solid tumors. The company's proprietary technology, MultiTAA-specific T cell therapy, is designed to selectively target tumor-associated antigens, offering a potentially more effective and safer alternative to conventional cancer treatments. Marker Therapeutics is focused on advancing its lead product candidates through clinical trials to address unmet medical needs in cancer care.

Marker Therapeutics (MRKR) Earnings & Revenues

Historic Earnings Reports

MRKR Stock 12 Month Forecast

Average Price Target

$8.00

▲(676.70% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"4":"$4","9":"$9","-1":"-$1","1.5":"$1.5","6.5":"$6.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":8,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$8.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":8,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$8.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":8,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$8.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[-1,1.5,4,6.5,9],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2024","6":"Feb<br/>2025","9":"May<br/>2025","12":"Oct<br/>2025","25":"Oct<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.908,1.4535384615384617,1.999076923076923,2.5446153846153847,3.090153846153846,3.6356923076923073,4.181230769230769,4.726769230769231,5.272307692307693,5.817846153846154,6.363384615384615,6.908923076923077,7.454461538461539,{"y":8,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.908,1.4535384615384617,1.999076923076923,2.5446153846153847,3.090153846153846,3.6356923076923073,4.181230769230769,4.726769230769231,5.272307692307693,5.817846153846154,6.363384615384615,6.908923076923077,7.454461538461539,{"y":8,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.908,1.4535384615384617,1.999076923076923,2.5446153846153847,3.090153846153846,3.6356923076923073,4.181230769230769,4.726769230769231,5.272307692307693,5.817846153846154,6.363384615384615,6.908923076923077,7.454461538461539,{"y":8,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":3.45,"date":1651363200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.6,"date":1711929600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.71,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.66,"date":1730419200000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":3.64,"date":1733011200000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":3.11,"date":1735689600000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 6</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":1.84,"date":1738368000000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":1.53,"date":1740787200000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":1.14,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.19,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.41,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.35,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.908,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >